Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 200Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 28Melanoma 26Adenocarcinoma of Lung 24Astrocytoma 21Stomach Neoplasms 20Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Esophageal Neoplasms 15Adenocarcinoma 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

pegfilgrastim 26Filgrastim 24Cyclophosphamide 8Docetaxel 7Etoposide 6pegylated granulocyte colony-stimulating factor 5Cytarabine 5eflapegrastim 4Granulocyte Colony-Stimulating Factor 4Leucovorin 3Fluorouracil 3Doxorubicin 3Cyclosporine 3Cefepime 3Caspofungin 3Carboplatin 3liposomal amphotericin B 2Vincristine 2Vancomycin 2Topotecan 2Methylprednisolone 2Methotrexate 2Itraconazole 2Irinotecan 2Ifosfamide 2Idarubicin 2Fluconazole 2Daunorubicin 2Cisplatin 2Amikacin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neutropenia × Bevacizumab × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡